Antibacterial and anti-breast cancer cell line activities of Sanghuangporus sp.1 extracts

Kusavadee Sangdee¹, Benjaporn Buranrat¹, Khwanyuruan Naksuwankul², Piyanoot Jaihan² and Aphidech Sangdee²,3*

¹Biomedical Sciences Research Unit, Faculty of Medicine, Mahasarakham University, Muang District, Mahasarakham 44000, Thailand
²Department of Biology, Faculty of Science, ³Microbiology and Applied Microbiology Research Unit, Faculty of Science, Mahasarakham University, Kantarawichai District, Mahasarakham 44150, Thailand

*For correspondence: Email: aphidech.s@msu.ac.th, aphidech_sangdee@yahoo.com; Tel: 6681-2615464; Fax: 6643-754245

Abstract

Purpose: To evaluate the activity of extracts of Sanghuangporus sp.1 fungus against pathogenic bacteria and a breast cancer cell line.

Methods: The wild fruiting body and mycelium of Sanghuangporus sp.1 were extracted with water and ethanol by ultrasonication extraction. The activity of the extracts against pathogenic bacteria was determined by agar-well diffusion method while minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were obtained by agar-well diffusion and broth macrodilution methods. The cytotoxicity of the extract against human breast cancer cell line MCF-7 was determined by sulforhodamine B assay.

Results: Only the ethanol mycelial extract exhibited antibacterial activity. Activity was detected against 6 of the 17 test strains of bacterial pathogen. The MICs and MBCs against these 6 strains were quite low, especially for B. cereus ATCC 11778 (2.5 and 2.5 mg/mL) and S. aureus (MSSA, DMST 2933, 2.5 and 5.0 mg/mL). The ethanol mycelial extract was more potently cytotoxic against MCF-7 cells than either the aqueous mycelial extract or the ethanol wild fruiting body extract, inhibiting cell growth at a concentration of 250 μg/mL. The aqueous wild fruiting body extract was inactive against MCF-7 cells when compared with untreated control groups.

Conclusion: The ethanol mycelial extract of the medicinal mushroom Sanghuangporus sp.1, obtained by ultrasonication extraction method, exhibited potent antibacterial and anticancer activity and seems to be a substitute for wild Sanghuangporus sp.

Keywords: Antibacterial activity, Anticancer activity, Sanghuangporus sp.1, Mycelial

INTRODUCTION

Mushrooms have been used as traditional remedies for many years [1], playing an important role in traditional medicine in Japan, China, Korea and other Asian countries [2]. The bioactivity of medicinal mushrooms is due to constituents such as polysaccharides, glycoproteins, proteoglycans, fatty acids and proteins [3]. Macrofungi in the genus Phellinus, especially Phellinus linteus, are reported to have many potentially salutary effects including immunomodulatory, anti-tumor, anti-oxidant, anti-inflammatory and antimicrobial activities [4-10]. For example, acidic polysaccharides isolated from P. linteus induce the functional maturation of dendritic cells [11], and inotilone has in vitro and in vivo anti-inflammatory activities that might be related to increased catalase, superoxide dismutase and glutathione peroxidase activity [7].
Hir et al [4] found that methanol extract from *P. linteus* inhibits the growth of methicillin-resistant *Staphylococcus aureus* (MRSA).

Another medicinal mushroom in this genus is *P. igniarius*. Song et al [12] have demonstrated that *P. igniarius* extracts inhibit the proliferation of human hepatocarcinoma SK-Hep-1 cell lines in a dose-dependent manner. A polyphenol extract from *P. igniarius* has been reported to protect against acrolein toxicity in vitro, and against stroke in a mouse model [13]. Chang et al. [14] and Ayala-Zavala et al. [6] found that extracts from *P. merrillii*, *P. gilvus*, *P. rimosus* and *P. badius* have antioxidant activity. Moreover, the extracts from *P. gilvus*, *P. rimosus* and *P. badius* could inhibit growth of the fungus *Alternaria alternata* [6]. Extracts from *P. baumii* have activity against influenza and methicillin-resistant *S. aureus* [15,16]. These findings indicate that many fungi in the genus *Phellinus* produce bioactive compounds, and represent a potential source of new therapeutic agents. Some of the above species have recently been reclassified, including *P. linteus*, which has been moved from the *Phellinus* genus to the *Sanghuangporus* genus, and is now known as *Sanghuangporus linteus*.

Many macrofungi in the genera *Phellinus* and *Sanghuangporus* have been found in the northeast of Thailand, but limited information is available on their bioactive compounds. Only 3 species, *P. igniarius*, *P. gilvus* and *P. merrillii*, have been reported to have antibacterial activity. Activity was detected against the pathogenic bacteria *Escherichia coli, Pseudomonas aeruginosa* and *S. aureus*, [17-19]. Other *Sanghuangporus* and *Phellinus* species merit investigation as source of new products that could be developed as novel therapeutic agents in the future. Therefore, the aim of the present study was to isolate the medicinal *Sanghuangporus* fungus from the wild fruiting body and then evaluate the activity of different extracts against Gram-negative and Gram-positive pathogenic bacteria by the agar well and macro-dilution method. The effect of these extracts on a breast cancer cell line was also examined.

**EXPERIMENTAL**

**Fungal isolation**

The wild fruiting body of the medicinal mushroom used in this study was provided by the Natural Medicinal Mushroom Museum, Mahasarakham University, Thailand (J. Naksuwankul 720 (MSUT)) (Figure 1). The *Sanghuangporus* sp.1 fungus fruiting bodies were washed several times with sterile distilled water and then the inner tissue of the fruiting bodies was cut into small pieces (5 x 5 mm²) before being surface sterilized and transferred to potato dextrose agar (PDA) containing 100 mg/mL ampicillin. After 7 days, the white mycelium growing out of the fungal tissue was sub-cultured on potato dextrose agar (PDA) and incubated at 25 - 28 °C.

**Preparation of extracts**

Mycelial discs of the *Sanghuangporus* sp.1 were cut with a sterile cork borer and placed into 25 mL of PDB medium. The culture was incubated statically at 28 °C for 20 days. The mycelium on the surface of the culture was collected and dried at 50 °C for 2 - 3 days before being powdered using a mortar and pestle. Five hundred milligram aliquots of the dried mycelium were placed in conical screw cap tubes and dissolved in either 12.5 mL of distilled water or 50 % ethanol. The mycelium suspension (40 mg/mL) was then sonicated using the ultrasonication extraction method described by Sangdee and Sangdee [20]. The dried wild fruiting body was cut into small pieces before being powdered using a mortar and pestle. Aqueous and ethanol extraction of the wild fruiting body was performed as described above.

**Test bacteria**


**Primary screening for antibacterial activity**

The antibacterial activity of the extracts was initially screened using an agar well diffusion method. The screening method was performed as described by Sangdee et al [21]. Briefly, the 15 test bacteria were cultured by inoculating a
single bacterial colony into Mueller Hinton broth (MHB), and then incubating with shaking (150 rpm) at 37 °C for 3 h. The cultures were then adjusted to the turbidity of a 0.5 McFarland standard. These cell suspensions were inoculated and spread over the entire surface of each Mueller Hinton agar (MHA) plate, and the agar plates were then cut using a sterile cork borer. Finally, 0.1 mL of 40 mg/mL of the extracts was added to each well (4 mg per well). After incubation at 37 °C for 16 – 18 h, the zones of inhibition in each plate were measured. Ciprofloxacin at a concentration of 250 μg/mL was used as a reference standard.

**Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays**

For extracts that showed a detectable zone of inhibition against the test bacteria, this activity was quantified by MIC and MBC assay. The MICs of the extracts were determined using the agar well diffusion method and broth macrodilution method. The agar well diffusion method was performed as described above, but testing a series of concentrations (40, 20, 10, 5, 2.5 and 1.25 mg/mL). The MIC represented the lowest concentration of extract capable of inhibiting bacterial growth around the well. The broth macrodilution method involved preparing a series of concentrations of extract (40, 20, 10, 5, 2.5 and 1.25 mg/mL) in MHB medium, then inoculating each with 0.1 mL of bacterial suspension. The final cell density of bacteria was 10^5 CFU/mL. The mixtures were incubated with shaking for 24 h (150 rpm). MICs were determined by identifying the solutions that were clear after incubation compared with the control tubes (MHB plus test bacteria, MHB plus the extracts, and MHB plus antibiotic and test bacteria). MBCs were determined by transferring bacterial suspensions from the MIC assay onto MHA plates. The lowest concentration that resulted in no growth after 24 h incubation was recorded as the MBC. Ciprofloxacin and tetracycline, each at a concentration of 250 μg/mL were used as reference standards. Two strains of methicillin-resistant *Staphylococcus aureus* (MRSA), viz, *S. aureus* DMST 4738 and *S. aureus* DMST 20654 at final cell density of 10^5 CFU/mL were used as test bacteria in the study.

**Evaluation of cytotoxicity against human breast cancer cells**

The effects of the extracts on the human breast cancer cell line MCF-7 were determined as described by Buranrat et al [22] using the sulforhodamine B (SRB) assay. Briefly, MCF-7 cells were seeded into a 96-well plate (1x10^4 cells/well) for 24 h before being exposed to the extracts at various concentrations for 72 h. After that, the cultured medium was removed, fixed with ice-cold methanol, stained with 0.4 % SRB, and solubilized with 10 mM Tris-base buffer. The absorbance was measured at 540 nm using a microplate reader compared with untreated control groups.

**RESULTS**

**Fungal isolation and colony morphology**

Within 7 - 10 days, the mycelium of the fungus *Sanghuangporus* sp.1 grew out of the tissue of the wild fruiting body and formed white colonies on PDA. The mycelium was sub-cultured onto a new PDA plate for morphological examination. After 3 - 5 days, the color of the colonies was white, these then changing to white-cream cottony colonies by 10 - 14 days. The colonies grew quickly, covering the surface of the 90 mm PDA plate by 21 days (Figure 1). This isolate was assigned the reference number *Sanghuangporus* sp.1.

**Antibacterial activity of mycelial and fruiting body extracts**

In this study, mycelial extracts and wild fruiting body extracts of *Sanghuangporus* sp.1 were tested against 15 strains of pathogenic bacteria using an agar well diffusion method. The results showed that only the ethanolic mycelial extract exhibited antibacterial activity. Activity was detected against 4 of the 15 test bacterial strains including *S. aureus* [MSSA] DMST 2933, *S. aureus* [MRSA] DMST 20651, *B. cereus* ATCC 11778 and *Vibrio cholerae* [O1] DMST 9700. The aqueous mycelial extract, aqueous wild fruiting body extract, and ethanolic wild fruiting body extract had no effect against the test bacteria. The inhibition zones of the ethanolic mycelial extract ranged from 11 - 24 mm, whereas the inhibition zones of the antibiotic ciprofloxacin ranged from 15 - 34 mm. Interestingly, 3 of the test bacteria, *B. cereus* ATCC 11778, *S. aureus* [MSSA] DMST 2933 and *S. aureus* [MRSA] DMST 20651, were more sensitive to the ethanolic extract than to ciprofloxacin. Moreover, *S. aureus* (MRSA) DMST 20651 was sensitive to the ethanolic mycelial extract, but resistant to ciprofloxacin (Table 1).

The MIC and MBC values of the ethanolic mycelial extract were determined against the sensitive strains above and against two strains of methicillin-resistant *Staphylococcus aureus*, strains DMST 4738 and DMST 20654.
Figure 1: Basidiocarp (A and B) and a colony of the medicinal mushroom *Sanghuangporus* sp.1 on PDA medium at 7, 14 and 22 days (C, D and E). (J. Naksuwankul 720 (MSUT)

Table 1: Primary antibacterial screening of the aqueous mycelial extract, ethanolic mycelial extract, aqueous fruiting body extract, and ethanolic fruiting body extract of *Sanghuangporus* sp.1 using the antibiotic ciprofloxacin as a reference standard.

<table>
<thead>
<tr>
<th>Test bacterium</th>
<th>Zone of inhibition (mm)</th>
<th>Mycelial extract</th>
<th>Fruiting body extract</th>
<th>Cipro (25 μg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Aqueous EtOH</td>
<td>Aqueous EtOH</td>
<td></td>
</tr>
<tr>
<td><em>B. cereus</em> ATCC 11778</td>
<td>0</td>
<td>23x23</td>
<td>0</td>
<td>15x15</td>
</tr>
<tr>
<td><em>S. aureus</em> (MSSA) DMST 2933</td>
<td>0</td>
<td>20x20</td>
<td>0</td>
<td>17x17</td>
</tr>
<tr>
<td><em>S. aureus</em> (MRSA) DMST 4738</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td><em>S. aureus</em> (MRSA) DMST 20651</td>
<td>0</td>
<td>24x24</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><em>S. aureus</em> (MRSA) DMST 20654</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td><em>V. cholerae</em> (O1) DMST 9700</td>
<td>0</td>
<td>11x11</td>
<td>0</td>
<td>34x34</td>
</tr>
<tr>
<td><em>E. coli</em> (EIEC) DMST 30545</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>13x13</td>
</tr>
<tr>
<td><em>E. coli</em> O157:H7 DMST 12743</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>25x25</td>
</tr>
<tr>
<td><em>Sh. flexneri</em> DMST 4423</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>26x26</td>
</tr>
<tr>
<td><em>Sh. flexneri</em> DMST 17569</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>29x29</td>
</tr>
<tr>
<td><em>S. Typhi</em> DMST 22842</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>30x30</td>
</tr>
<tr>
<td><em>S. Typhi</em> DMST 16122</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>25x25</td>
</tr>
<tr>
<td><em>Sh. dysenteriae</em> DMST 15110</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>30x30</td>
</tr>
<tr>
<td><em>S. Typhimurium</em> ATCC 14028</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>26x26</td>
</tr>
<tr>
<td><em>Ps. aeruginosa</em> ATCC 27853</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>27x27</td>
</tr>
<tr>
<td><em>Ps. aeruginosa</em></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>18x18</td>
</tr>
<tr>
<td><em>K. pneumonia</em></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>23x23</td>
</tr>
</tbody>
</table>

EtOH, ethanol; Cipro, ciprofloxacin; ND, not determined; MIC, minimum inhibitory concentration; MBC, minimum bactericidal concentration

The MICs of the ethanolic mycelial extract were quite low ranging from 2.5-10 mg/mL by the agar well diffusion method. The MIC values of the same extract measured by the broth macrodilution method were 2.5-5 mg/mL. *B. cereus* ATCC 11778 and *S. aureus* [MSSA] DMST 2933 were the most sensitive. The MBC values of the ethanolic mycelial extract ranged from 2.5-5.0 mg/mL, with *B. cereus* ATCC 11778 being the most sensitive (Table 2).
Table 2: MIC and MBC values of the ethanolic mycelial extract of *Sanghuangporus* sp.1 against 6 strains of pathogenic bacteria

<table>
<thead>
<tr>
<th>Test bacterium</th>
<th>MIC (mg/mL)</th>
<th>MBC (mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Agar well method</td>
<td>Broth macrodilution method</td>
</tr>
<tr>
<td><strong>B. cereus</strong> ATCC 11778</td>
<td>2.5</td>
<td>2.5</td>
</tr>
<tr>
<td><strong>S. aureus</strong> (MSSA) DMST 2933</td>
<td>2.5</td>
<td>2.5</td>
</tr>
<tr>
<td><strong>S. aureus</strong> (MRSA) DMST 20651</td>
<td>10.0</td>
<td>5.0</td>
</tr>
<tr>
<td><strong>S. aureus</strong> (MRSA) DMST 4738</td>
<td>5.0</td>
<td>5.0</td>
</tr>
<tr>
<td><strong>S. aureus</strong> (MRSA) DMST 20654</td>
<td>10.0</td>
<td>5.0</td>
</tr>
<tr>
<td><strong>V. cholerae</strong> (O1) DMST 9700</td>
<td>10.0</td>
<td>5.0</td>
</tr>
</tbody>
</table>

Cytotoxicity against human breast cancer cells

The cytotoxicity of the extracts against MCF-7 cells was evaluated using the SRB assay. The results showed that MCF-7 cells were more sensitive to the mycelial extracts than the wild fruiting body extracts. The ethanolic mycelial extract had greater cytotoxicity against the MCF-7 cells than either the aqueous mycelial extract or the ethanolic wild fruiting body extract. No activity was detected from the aqueous wild fruiting body extract against the MCF-7 cells. At 72 h, the aqueous and ethanolic mycelial extracts at concentrations of 500 μg/mL and 250 μg/mL inhibited MCF-7 cell growth when compared to untreated cells (Figure 2). Moreover, the results showed that cell growth was strongly inhibited by ethanolic mycelial extracts in a dose-dependent manner with an IC$_{50}$ value of 1122.67 ± 203.09 μg/mL, while no activity was detected from the aqueous wild fruiting body extract against the MCF-7 cells.

![Figure 2](image-url):
Figure 2: Effect of the aqueous mycelial extract (A), ethanol mycelial extract (B), aqueous wild fruiting body extract (C) and ethanol fruiting body extract (D) of *Sanghuangporus* sp.1 on the growth of MCF-7 cells. The cells were cultured for 24 h in 96-well plates and then treated with various concentrations of the extracts for 72 h before cell viability was determined by the SRB assay. The bars show mean ± SEM, each from three independent experiments; *p < 0.05 vs. untreated control groups
DISCUSSION

In recent years, it has been proposed that several mushrooms belonging to the genera *Sanghuangporus*, *Phellinus* and *Inonotus*, such as *S. linteus*, *Inonotus obliquus*, *I. xeranticus* and *P. ignarius* could be used as nutritionally functional foods or as sources of medicinally useful compounds [23]. Examples of bioactive constituents include polysaccharides, especially β-glucan, which enhances immune system activity [24]. They also produce compounds with antioxidant activity [25,26]. In the present study, *Sanghuangporus* sp.1 was isolated and screened for antibacterial and anticancer activities.

The activity of artificially cultivated *Sanghuangporus* sp.1 extracts were compared with those of the wild fruiting body. The results indicate that the ethanolic mycelial extract has superior activity against *S. aureus* [MSSA] DMST 2933, *S. aureus* [MRSA] DMST 20651, *S. aureus* [MRS] DMST 4738, *S. aureus* [MRSA] DMST 20654, *B. cereus* ATCC 11778 and *Vibrio cholerae* [O1] DMST 9700 than extracts from the wild fruiting body. Interestingly, the ethanolic mycelial extract had activity against the medically important pathogenic bacteria *S. aureus* [MSSA] DMST 2933, *S. aureus* (MRSA) DMST 20651 and *S. aureus* (MRSA) DMST 20654, the latter 2 strains being resistant to ciprofloxacin. These results correlate well with those of Hur et al [4], who demonstrated that extracts from *S. linteus* have good activity against methicillin-resistant *Staphylococcus aureus*.

Similar findings to those above were observed in the cytotoxicity assay, with both mycelial extracts having greater cytotoxicity against the MCF-7 breast cancer cell line than the wild fruiting body extracts. These results indicate that mycelia cultivated in the laboratory are more bioactive, and may produce more potent medicinal compounds. These results correlate well with those of Sun et al [27], who demonstrated that artificially cultivated *I. obliquus* have similar inhibitory activity against tumor cells and bioactive compounds as wild *I. obliquus*. Our findings also suggest that the bioactivity of the ethanolic mycelial extract of *Sanghuangporus* sp.1 is significantly greater than the other extracts.

This comparative study indicates that the medicinal mushroom *Sanghuangporus* sp.1 can be grown in the laboratory and used as a source of broad-spectrum antibacterial and anticancer agents. It can therefore be considered an alternative to wild *Sanghuangporus* spp.

However, further studies will be required to isolate and identify the compounds responsible for the anticancer properties of the extracts and elucidate the mechanism of action of ethanolic mycelial extract against breast and other cancer cells.

Finally, the extraction procedure is important for isolating active components from many organisms including plants [28] and fungi [29]. In this study, we used the ultrasonication method to isolate bioactive compounds from both fungal mycelia and the fruiting body. The results indicate that this method does extract compounds with antibacterial and anticancer activity. However, other parameters including the type of solvent should be considered, because different solvents have different polarities, and therefore extract compounds of different polarities. For example, the ethanolic mycelial extract showed more antibacterial and anti-breast cancer cell line activity than those of the aqueous mycelial extract. These observations may be due to different bioactive compounds being extracted or different quantities of bioactive compound being extracted. Suitable extraction methods and extraction parameters should therefore be identified before large scale production of the bioactive compounds is attempted.

CONCLUSION

This study shows that extracts of the medicinal mushroom *Sanghuangporus* sp.1 exhibit significant *in vitro* antibacterial and anticancer activities. Furthermore, the extracts of laboratory-grown *Sanghuangporus* sp.1 mycelia are at least as active as those of the wild fruiting body of *Sanghuangporus* sp.1, and can therefore be used as a source of bioactive agents. Further studies are, however, required to isolate and identify the compounds responsible for the antibacterial and anticancer activities of *Sanghuangporus* sp.1.

DECLARATIONS

Acknowledgement

The authors are grateful to Mahasarakham University Faculty of Medicine for equipment support and language-editing assistance, and Mahasarakham University Faculty of Science for provision of laboratory space and equipment. We would also like to thank Ms. Jitdakan Naksuwankul, who collected mushroom sample and deposited it at Natural Medicinal Mushroom Museum, Mahasarakham University, Thailand.
Conflict of Interest

No conflict of interest associated with this work.

Contribution of Authors

The authors declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by them.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/rea) which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES

22. Buranrat B, Senggunprai L, Prawan A, Kukongviriyapan V. Simvastatin and atorvastatin as inhibitors of...